2026-10-02 Capital
Novartis signs up to $7.8B mRNA licensing deal with China's Abogen Big pharma doubles down on China innovation; deal among largest announced recently
D1 +0.0% · +5d +2.0%
2026-09-10 → 09-16 Company Bear
Novartis M&A strategy questioned, shareholders push governance reform after trial setbacks ALS drug failure intensifies scrutiny of Novartis R&D and M&A strategy, shareholder pressure persists
D1 +0.0% · +5d +2.5%
› 3 waves of this story2026-09-10 After trial setbacks and $30B market cap loss, governance under fire; company reiterates guidance2026-09-11 Multiple sources report investor scrutiny of M&A following trial setbacks, echoing existing event.2026-09-16 ALS drug failure intensifies scrutiny of Novartis R&D and M&A strategy, shareholder pressure persists10 earlier events › 2026-09-16 Company Bear
Novartis halts ALS drug development after mid-stage trial failure Another R&D setback this year after del-desiran Phase III failure, ALS pipeline hit
D1 +0.1% · +5d +2.9%
2026-09-10 Analyst
HSBC upgrades to Hold D1 +0.0% · +5d +2.5%
2026-09-05 → 09-09 Product Bear
Novartis del-desiran fails Phase 3, shares fall 10% HARBOR miss heightens pipeline risk concerns
D1 -13.9% · +5d +0.7%
› 4 waves of this story2026-09-05 HORIZON trial failed to cut cardiovascular events despite Lp(a) reduction2026-09-07 Multiple sources confirm pelacarsen missed primary endpoint, raising pipeline concerns2026-09-08 After pelacarsen, del-desiran misses primary endpoint in HARBOR study, adding pipeline pressure2026-09-09 HARBOR miss heightens pipeline risk concerns2026-09-01 → 09-03 Product Bull
Novartis' Remibrutinib Meets Primary Endpoint in Phase III MS Studies, Slashes Relapse Rate Zacks confirms remibrutinib significantly reduced annualized relapse rates vs Aubagio in relapsing MS
D1 +6.0% · +5d -14.7%
› 3 waves of this story2026-09-01 Oral BTK inhibitor beats teriflunomide in reducing relapse rates in RMS2026-09-03 Both Phase III studies show superiority over Aubagio, strengthening oral MS franchise2026-09-03 Zacks confirms remibrutinib significantly reduced annualized relapse rates vs Aubagio in relapsing MS2026-09-02 Capital
Novartis signs up to $3.2B deal for Alteogen's drug delivery tech Gains subcutaneous injection tech, expands pipeline, but with high milestone payments
D1 +0.8% · +5d -15.4%
2026-09-01 Company Bear
Novartis Halts 8 CAR-T Trials After 3 Patient Deaths Multiple sources confirm trial pause in autoimmune/neurology cell therapy
D1 +6.0% · +5d -14.7%
2026-07-21 Earnings
Earnings report Q2 net sales grew 1% in constant currencies to $14.4 billion; core operating income flat at $5.9 billion with 41.2% margin
D1 +2.9% · +5d +3.9%
2026-07-21 Earnings Bull
Novartis Q2 core operating profit beats expectations Q2 revenue and EPS beat estimates, core operating profit grew, FY26 guidance reaffirmed.
D1 +2.9% · +5d +3.9%
› 2 waves of this story2026-07-21 Q2 core operating profit beat on strong cancer/MS drug sales, despite 50% Entresto drop2026-07-21 Q2 revenue and EPS beat estimates, core operating profit grew, FY26 guidance reaffirmed.2026-07-20 Product
Novartis faces pipeline test with valuation premium in focus Reuters reports investors focus on three major drug trial readouts in H2 to justify premium valuation
D1 -2.7% · +5d +4.4%
2026-07-20 Capital
Multiple funds adjust Novartis stakes; Dimensional holds $1.24B Boston Common sold 5,150 shares; Dimensional cut 4.9% but retains $1.24B stake
D1 -2.7% · +5d +4.4%
› 2 waves of this story2026-07-20 Boston Common cut 4.5%, Dimensional cut 4.9% but stake remains $1.24B2026-07-20 Boston Common sold 5,150 shares; Dimensional cut 4.9% but retains $1.24B stakeby direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
